Última actualización 12 de septiembre de 2026
Key finding
Finerenone reduces levels of albuminuria.
This study investigated the effects of Finerenone on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease, finding significant reductions in various health outcomes.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study investigated the effects of Finerenone on patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease, finding significant reductions in various health outcomes.
The findings are clinically significant as they suggest that Finerenone could be a valuable treatment option for managing complications associated with Type 2 Diabetes and Chronic Kidney Disease. By effectively reducing albuminuria and the risk of kidney failure and cardiovascular events, Finerenone may improve patient outcomes and quality of life.
Effectiveness data was unclear for several outcomes. No specific p-values were provided for the findings. The study may have limitations in generalizability.
Published in
Publication details and source links for this paper.
Talia R, Ilana R, Devendra KA. Finerenone: A Novel Therapeutic Option for Patients with Type 2 Diabetes Mellitus and Chronic Kidney Disease. Archives of internal medicine research. 2026;9(2):94-106. doi:10.26502/aimr.0241
Finerenone reduced levels of albuminuria.
Finerenone reduced the incidence of kidney failure.
Finerenone reduced cardiovascular events such as myocardial infarction and stroke.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Albuminuria, Cardiovascular events, Cardiovascular mortality, and 3 more.
This study contributes evidence to
Primary intervention
Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Primary outcomes
Evidence topics
Primary intervention
Primary outcomes
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
2
Related topics
6
Evidence pairs
195
Related studies
Evidence topic
Contributes evidence
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_intervention_and_outcome
Evidencia relacionada
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Albuminuria
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Albuminuria
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular events
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular events
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular mortality
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Cardiovascular mortality
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Estimated glomerular filtration rate
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Estimated glomerular filtration rate
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of hyperkalemia
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of kidney failure
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) → Incidence of kidney failure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Finerenone (nonsteroidal mineralocorticoid receptor antagonist) and Incidence of hyperkalemia.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies on Finerenone (nonsteroidal mineralocorticoid receptor antagonist)
Contributes to Finerenone (nonsteroidal mineralocorticoid receptor antagonist) evidence base.
All studies measuring Incidence of hyperkalemia
Measures Incidence of hyperkalemia as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
3 results
3 results
3 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear reduction in incidence of hyperkalemia with Finerenone (nonsteroidal mineralocorticoid receptor antagonist).
ConsistencyScore™: Results are generally consistent across studies.
Ranked evidence signals
Incidence of hyperkalemia
EvidenceScore™ Strong | EvidenceScore™ 77.1 | neutral | ConsistencyScore™ Generally Consistent | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Finerenone (nonsteroidal mineralocorticoid receptor antagonist) appears to reduce incidence of kidney failure.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Incidence of kidney failure
EvidenceScore™ Unknown | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for albuminuria.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Albuminuria
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Finerenone (nonsteroidal mineralocorticoid receptor antagonist) for cardiovascular events.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Cardiovascular events
EvidenceScore™ Unknown | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Follow the topics this study contributes to.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
